Cell Separation & Characterization in Solid Tumors: Global Markets Through 2023 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 17, 2018--The “Cell Separation and Characterization in Solid Tumors: Global Markets Through 2023” report has been added to ResearchAndMarkets.com’s offering.
This report consists of the overall analysis of the market landscape.
It provides in-depth analysis on market size, growth opportunity in market and product types. The report will serve as a source for 360-degree analysis of the market, thoroughly integrating different models.
The report will help the companies and organizations have an all-around analysis of the cell separation and characterization in the solid tumor market and the most preferred markets regionally.
The report includes:An overview of the global markets and technologies for cell separation and characterization in solid tumors Analyses of global market trends with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Overview of the main markers used for isolation, identification and purification for solid tumors, including surface cell-adhesion molecules such as CD133, CD24, hyaluronic acid (HA) receptor CD44, cytoprotective enzymes such as aldehyde dehydrogenase, ALDH, and transcription factors OCT-4, SOX-2 Discussion of the various cell separation technique and technologies such as fluorescence-activated cell sorting (FACS), magnet-activated cell sorting (MACS), density gradient centrifugation, dielectrophoretic (DEP), aqueous two-phase system, field flow fractionation (FFF) and microfluidic platforms Coverage of the major products of the industry such as solid tumor kits, multi-marker solid tumor panels, reagents and microchips and micro-beads Comprehensive analysis of the major companies active in the market, including Abbvie, Inc., AstraZeneca, Beckman Coulter, Daiichi Sankyo and Pfizer, Inc.
Companies ProfiledAAT Bioquest AbbVie, Inc. Abcodia Ltd. AstraZeneca Astrazeneca Beckman Coulter Bio-Techne Corp. Cayman Chemical Cell Biolabs, Inc. Daiichi Sankyo Eisai Co. Ltd. Epizyme, Inc. Genmab A/S Gilead Sciences, Inc. Glaxosmithkline Plc Illumina, Inc. Janssen Lidds Merck Miltenyi Biotech MP Biomedicals Neogenomics Novocure NSJ Bioreagents Onconova Therapeutics Perkinelmer, Inc. Pfizer Corp. Propanc Biopharma, Inc. R&D Activities Recent Activities Regnix Taiho Pharma Tesaro, Inc. Thermo Fisher Scientific and more...
For more information about this report visit https://www.researchandmarkets.com/research/6fjwhz/cell_separation?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181217005724/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/17/2018 01:42 PM/DISC: 12/17/2018 01:42 PM